Physician profile

Saheed Ojo-Oniyun

Internal Medicine · King of Prussia, PA

NPI 1649333071

$491.52

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$94.28

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $167.03 2019-2022
Alkermes, INC. $100.01 2019
Pfizer INC. $98.06 2019
Astrazeneca Pharmaceuticals LP $51.26 2023 Breztri
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $24.75 2023 Xifaxan
Inari Medical, INC. $18.27 2023 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Melinta Therapeutics, LLC $17.49 2019
Vifor Pharma, INC. $14.65 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Saheed Ojo-Oniyun

$491.52

in general payments reported 2019-2025

Years
2019-2023
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/1300895/saheed-ojo-oniyun

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.